Exane Derivatives Biocryst Pharmaceuticals Inc Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Exane Derivatives holds 32 shares of BCRX stock, worth $344. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32
Previous 7,527
99.57%
Holding current value
$344
Previous $122,000
100.0%
% of portfolio
0.0%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding BCRX
# of Institutions
293Shares Held
177MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$233 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$215 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$96 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$93.5 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$84 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $2B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...